Regeneus Ltd, a clinical-stage regenerative medicine company, engages in developing cell-based therapies for the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, and neuropathic pain and dermatology diseases. The company is developing its therapeutic products using its proprietary stem cell and immuno-oncology technology platforms. Its products under development for human health market include Progenza, a cell therapy that has completed Phase I clinical trial for the treatment of osteoarthritis and other musculoskeletal disorders; RGSH4K, a cancer vaccine, which is in Phase I clinical trial for the treatment of solid tumors; and Sygenus allogeneic cell secretion for use as a topical application for the treatment of acne and other inflammatory skin conditions, and wound healing. The company's animal health products comprise CryoShot, an allogeneic mesenchymal stem cell therapy for the treatment of canine osteoarthritis and other musculoskeletal disorders; and Kvax, an autologous cancer vaccine. Regeneus Ltd was founded in 2007 and is headquartered in Paddington, Australia.